 Connection
Paul Bunn to Topoisomerase I Inhibitors
This is a "connection" page, showing publications Paul Bunn has written about Topoisomerase I Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.236 |
|
|
|
-
Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs. 2017 11; 28(10):1086-1096.
Score: 0.145
-
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA. RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. J Clin Oncol. 2024 Jul 01; 42(19):2317-2326.
Score: 0.057
-
Bunn PA. Future directions in therapeutic approaches for small cell lung cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 16):136-8.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|